Referring to a triazolopiridina Derivative of formula (i), where the Ring members together with the ring (6) are structures (a), (b), (c) or (d) r1 is H, alkyl aryl C6 C1 - C6, C8 and C14, cycloalkyl, among others R2 is H, alkyl aryl C6 C1 - C10, C14, among others R3 is H, halogen, alkyd ILO C1 - C6 C6 C14, aryl, among others R4 and R5 are Halogen, alkyl of C1 - C6.Preferred compounds are: {acid 5 - [(3 - 5 - fluoro - hydroxy trifluorometilfenil) - 7 - [1,2,4] triazolo [1,5-a] pyridin - 8 - carbonyl] amino} acetic acid (7 - [- 5 - hydroxy pentyl [1,2,4] triazolo [1,5-a] pyridin - 8 - carbonyl) amino] acetic Acid 5 - [(3 - 5 - 4-fluorophenyl cyclopropyl - hydroxy) - 7 - [1,2,4] triazolo [1,5-a] pyridin - 8 - C Arbonil] amino} acetic acid, among others. It also relates to a Pharmaceutical composition.These compounds have Inhibitory activity of prolyl hydroxylase (PhD) and the capacity of Inducing the production of erythropoietin (EPO) and are useful in the treatment of ischemic heart disease, Chronic Kidney Failure, diabetic complications, includingREFERIDA A UN DERIVADO DE TRIAZOLOPIRIDINA DE FORMULA (I), DONDE EL ANILLO DE 6 MIEMBROS UNIDO AL ANILLO (A) FORMAN LAS ESTRUCTURAS (a), (b), (c) O (d) R1 ES H, ALQUILO C1-C6, ARILO C6-C14, CICLOALQUILO C3-C8, ENTRE OTROS R2 ES H, ALQUILO C1-C10, ARILO C6-C14, ENTRE OTROS R3 ES H, HALOGENO, ALQUILO C1-C6, ARILO C6-C14, ENTRE OTROS R4 Y R5 SON HALOGENO, ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS: ACIDO {[5-(3-FLUORO-5-TRIFLUOROMETILFENIL)-7-HIDROXI[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-8-CARBONIL]AMINO}ACETICO, ACIDO [(7-HIDROXI-5-PENTIL[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-8-CARBONIL)AMINO]ACETICO, ACIDO {[5-(3-CICLOPROPIL-5-FLUOROFENIL)-7-HIDROXI[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-8-CARBONIL]AMINO}ACETICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD INHIBIDORA DE LA PROLIL HIDROXILASA (PHD) Y LA CAPACIDAD DE INDUCIR LA PRODUCCION DE ERITROPOYETINA (EPO) Y SON UTILES EN EL TRATAMIENTO DE ENF
